MaxCyte Inc (NASDAQ:MXCT) shares rose over 9% following the announcement of strong preliminary Q4 and full-year 2023 revenue results, surpassing consensus estimates. Q4 revenue is projected between $15.5 million and $15.7 million, with core revenue between $7.0 million and $7.2 million, and SPL Program-related revenue around $8.5 million. For FY23, revenue is expected to be between $41.1 million and $41.3 million, against a consensus of $36.72 million. The company's cash position as of December 31, 2023, was approximately $210 million. CEO Maher Masoud expressed confidence in the company's future despite a challenging operating environment in 2023. Full Q4 results are anticipated to be released in March 2024.